Research.Patient.info

Advanced dedifferentiated liposarcoma research hub

1 indexed studies · 0 currently recruiting

ongoing, recruitingPhase II and Phase III (Integrated)
Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
Netherlands · Belgium · Czechia